Xenon Pharmaceuticals Unveils Q1 2024 Results

TipRanksMay 3 04:37

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial

GlobeNewswireMay 3 04:01

Xenon Pharmaceuticals Spotlights XEN1101 Progress

TipRanksApr 16 21:08

Xenon Pharmaceuticals Announced Two Oral Presentations For XEN1101 Clinical Data At AAN 2024 Annual Meeting

Xenon's Oral Presentations at AANOral Presentation #005 (French et al.) "Interim, Long-term, Safety and Efficacy of XEN1101, a Potent, Selective Potassium Channel Opener: Update from an Ongoing Open-l

BenzingaApr 16 20:41

Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $62 Price Target

Needham analyst Serge Belanger reiterates Xenon Pharmaceuticals with a Buy and maintains $62 price target.

Analyst UpgradesApr 12 19:03

Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target

Cantor Fitzgerald analyst Josh Schimmer reiterates Xenon Pharmaceuticals with a Overweight and maintains $65 price target.

Analyst UpgradesApr 10 21:47